CAI logo

Caris Life Sciences, Inc. (CAI) EBITDA

annual EBITDA:

-$182.95M+$77.85M(+29.85%)
December 1, 2024

Summary

  • As of today (August 26, 2025), CAI annual EBITDA is -$182.95 million, with the most recent change of +$77.85 million (+29.85%) on December 1, 2024.
  • During the last 3 years, CAI annual EBITDA has risen by +$62.94 million (+25.60%).
  • CAI annual EBITDA is now -171.31% below its all-time high of $256.55 million, reached on December 1, 2018.

Performance

CAI EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCAIincome statement metrics

quarterly EBITDA:

-$11.59M+$39.32M(+77.23%)
June 1, 2025

Summary

  • As of today (August 26, 2025), CAI quarterly EBITDA is -$11.59 million, with the most recent change of +$39.32 million (+77.23%) on June 1, 2025.
  • Over the past year, CAI quarterly EBITDA has increased by +$43.82 million (+79.09%).
  • CAI quarterly EBITDA is now -115.52% below its all-time high of $74.67 million, reached on September 30, 2021.

Performance

CAI quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCAIincome statement metrics

TTM EBITDA:

-$62.49M+$43.82M(+41.22%)
June 1, 2025

Summary

  • As of today (August 26, 2025), CAI TTM EBITDA is -$62.49 million, with the most recent change of +$43.82 million (+41.22%) on June 1, 2025.
  • Over the past year, CAI TTM EBITDA has increased by +$67.44 million (+51.90%).
  • CAI TTM EBITDA is now -124.54% below its all-time high of $254.62 million, reached on September 30, 2021.

Performance

CAI TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCAIincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

CAI EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+29.9%+79.1%+51.9%
3 y3 years+25.6%+84.5%+16.1%
5 y5 years-172.8%-127.6%-139.0%

CAI EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-171.9%+29.9%-115.5%+84.5%-124.5%+51.9%
5 y5-year-171.9%+29.9%-115.5%+84.5%-124.5%+51.9%
alltimeall time-171.3%+29.9%-115.5%+84.5%-124.5%+51.9%

CAI EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$11.59M(-77.2%)
-$62.49M(-41.2%)
Mar 2025
-
-$50.91M(-8.1%)
-$106.32M(-18.2%)
Dec 2024
-$182.95M(-29.9%)
-
-
Jun 2024
-
-$55.41M(-25.6%)
-$129.93M(+74.4%)
Mar 2024
-
-$74.52M(-199.8%)
-$74.52M(-129.3%)
Dec 2023
-$260.80M(+6.1%)
-
-
Dec 2022
-$245.89M(-196.6%)
-
-
Sep 2021
-
$74.67M(+20.1%)
$254.62M(+11.5%)
Jun 2021
-
$62.17M(+4.3%)
$228.29M(+9.7%)
Mar 2021
-
$59.61M(+2.5%)
$208.06M(+10.6%)
Dec 2020
$254.46M(+1.2%)
$58.16M(+20.3%)
$188.17M(+12.2%)
Sep 2020
-
$48.34M(+15.2%)
$167.71M(+4.6%)
Jun 2020
-
$41.95M(+5.6%)
$160.28M(-1.2%)
Mar 2020
-
$39.73M(+5.4%)
$162.19M(-2.4%)
Dec 2019
$251.43M(-2.0%)
-
-
Dec 2019
-
$37.70M(-7.9%)
$166.15M(-5.4%)
Sep 2019
-
$40.91M(-6.7%)
$175.56M(-4.6%)
Jun 2019
-
$43.86M(+0.4%)
$184.08M(+0.9%)
Mar 2019
-
$43.68M(-7.3%)
$182.50M(-0.7%)
Dec 2018
$256.55M(+28.4%)
$47.11M(-4.7%)
$183.87M(+7.3%)
Sep 2018
-
$49.43M(+16.9%)
$171.34M(+2.9%)
Jun 2018
-
$42.28M(-6.1%)
$166.49M(+2.4%)
Mar 2018
-
$45.05M(+30.3%)
$162.53M(+6.6%)
Dec 2017
$199.75M(+25.4%)
$34.58M(-22.4%)
$152.49M(+3.3%)
Sep 2017
-
$44.58M(+16.3%)
$147.66M(+13.7%)
Jun 2017
-
$38.32M(+9.5%)
$129.90M(+7.7%)
Mar 2017
-
$35.01M(+17.7%)
$120.61M(+2.9%)
Dec 2016
$159.31M(-12.2%)
$29.75M(+10.9%)
$117.21M(-20.8%)
Sep 2016
-
$26.82M(-7.6%)
$147.97M(-6.4%)
Jun 2016
-
$29.04M(-8.1%)
$158.16M(-4.4%)
Mar 2016
-
$31.60M(-47.8%)
$165.39M(-2.5%)
Dec 2015
$181.49M(-0.1%)
$60.51M(+63.5%)
$169.71M(+47.2%)
Sep 2015
-
$37.01M(+2.0%)
$115.25M(-8.2%)
Jun 2015
-
$36.27M(+0.9%)
$125.52M(-5.5%)
Mar 2015
-
$35.93M(+493.8%)
$132.88M(-5.3%)
Dec 2014
$181.62M
$6.05M(-87.2%)
$140.27M(+2.3%)
DateAnnualQuarterlyTTM
Sep 2014
-
$47.27M(+8.4%)
$137.17M(+2.5%)
Jun 2014
-
$43.63M(+0.7%)
$133.85M(-0.6%)
Mar 2014
-
$43.32M(+1368.0%)
$134.71M(+0.7%)
Dec 2013
$175.99M(+15.3%)
$2.95M(-93.3%)
$133.82M(-23.5%)
Sep 2013
-
$43.95M(-1.2%)
$174.96M(+3.0%)
Jun 2013
-
$44.49M(+4.8%)
$169.91M(+5.4%)
Mar 2013
-
$42.44M(-3.8%)
$161.18M(+5.6%)
Dec 2012
$152.65M(+34.6%)
$44.09M(+13.4%)
$152.65M(+8.5%)
Sep 2012
-
$38.90M(+8.8%)
$140.70M(+6.2%)
Jun 2012
-
$35.76M(+5.5%)
$132.49M(+9.0%)
Mar 2012
-
$33.90M(+5.4%)
$121.55M(+7.2%)
Dec 2011
$113.37M(+90.6%)
$32.15M(+4.8%)
$113.37M(+10.1%)
Sep 2011
-
$30.69M(+23.6%)
$102.96M(+16.7%)
Jun 2011
-
$24.82M(-3.5%)
$88.19M(+16.3%)
Mar 2011
-
$25.71M(+18.3%)
$75.83M(+27.5%)
Dec 2010
$59.48M(+46.1%)
$21.74M(+36.6%)
$59.48M(+26.8%)
Sep 2010
-
$15.92M(+27.7%)
$46.92M(+15.4%)
Jun 2010
-
$12.46M(+33.2%)
$40.67M(+5.9%)
Mar 2010
-
$9.36M(+1.9%)
$38.39M(-5.7%)
Dec 2009
$40.72M(+254.8%)
$9.18M(-5.0%)
$40.72M(-2024.3%)
Sep 2009
-
$9.67M(-5.1%)
-$2.12M(-146.0%)
Jun 2009
-
$10.19M(-12.8%)
$4.60M(-54.6%)
Mar 2009
-
$11.68M(-134.7%)
$10.12M(-13.2%)
Dec 2008
$11.47M(-77.4%)
-$33.65M(-305.4%)
$11.66M(-80.8%)
Sep 2008
-
$16.38M(+4.3%)
$60.60M(+5.0%)
Jun 2008
-
$15.71M(+18.8%)
$57.74M(+9.4%)
Mar 2008
-
$13.22M(-13.5%)
$52.76M(+4.0%)
Dec 2007
$50.71M(+239.9%)
$15.29M(+13.1%)
$50.71M(+152.1%)
Sep 2007
-
$13.52M(+26.1%)
$20.12M(+8.5%)
Jun 2007
-
$10.72M(-4.1%)
$18.54M(+3.8%)
Mar 2007
-
$11.18M(-173.0%)
$17.87M(+167.1%)
Dec 2006
$14.92M(-61.7%)
-$15.30M(-228.2%)
$6.69M(-69.6%)
Sep 2006
-
$11.94M(+18.8%)
$22.00M(+118.8%)
Jun 2006
-
$10.05M
$10.05M
Dec 2005
$39.00M(+1.2%)
-
-
Dec 2004
$38.55M(+102.4%)
-
-
Dec 2003
$19.05M
-
-

FAQ

  • What is Caris Life Sciences, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Caris Life Sciences, Inc.?
  • What is Caris Life Sciences, Inc. annual EBITDA year-on-year change?
  • What is Caris Life Sciences, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Caris Life Sciences, Inc.?
  • What is Caris Life Sciences, Inc. quarterly EBITDA year-on-year change?
  • What is Caris Life Sciences, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Caris Life Sciences, Inc.?
  • What is Caris Life Sciences, Inc. TTM EBITDA year-on-year change?

What is Caris Life Sciences, Inc. annual EBITDA?

The current annual EBITDA of CAI is -$182.95M

What is the all time high annual EBITDA for Caris Life Sciences, Inc.?

Caris Life Sciences, Inc. all-time high annual EBITDA is $256.55M

What is Caris Life Sciences, Inc. annual EBITDA year-on-year change?

Over the past year, CAI annual EBITDA has changed by +$77.85M (+29.85%)

What is Caris Life Sciences, Inc. quarterly EBITDA?

The current quarterly EBITDA of CAI is -$11.59M

What is the all time high quarterly EBITDA for Caris Life Sciences, Inc.?

Caris Life Sciences, Inc. all-time high quarterly EBITDA is $74.67M

What is Caris Life Sciences, Inc. quarterly EBITDA year-on-year change?

Over the past year, CAI quarterly EBITDA has changed by +$43.82M (+79.09%)

What is Caris Life Sciences, Inc. TTM EBITDA?

The current TTM EBITDA of CAI is -$62.49M

What is the all time high TTM EBITDA for Caris Life Sciences, Inc.?

Caris Life Sciences, Inc. all-time high TTM EBITDA is $254.62M

What is Caris Life Sciences, Inc. TTM EBITDA year-on-year change?

Over the past year, CAI TTM EBITDA has changed by +$67.44M (+51.90%)
On this page